ScoreWhy is Balaxi Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -4.77% CAGR growth in Operating Profits
2
Negative results in Sep 25
- PAT(9M) At Rs 9.14 cr has Grown at -56.40%
- NET SALES(Q) At Rs 56.18 cr has Fallen at -27.40%
- PBT LESS OI(Q) At Rs -0.21 cr has Fallen at -102.17%
3
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -5.37% over the previous quarter and collectively hold 3.52% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
4
Below par performance in long term as well as near term
- Along with generating -100.00% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Balaxi Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Balaxi Pharma
-59.38%
-1.21
49.02%
Sensex
4.83%
0.41
11.83%
Management Risk
Growth
Capital StructureValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.79
EV to EBIT
10.31
EV to EBITDA
9.42
EV to Capital Employed
0.81
EV to Sales
0.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.81%
ROE (Latest)
6.09%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-16What is not working for the Company
PAT(9M)
At Rs 9.14 cr has Grown at -56.40%
NET SALES(Q)
At Rs 56.18 cr has Fallen at -27.40%
PBT LESS OI(Q)
At Rs -0.21 cr has Fallen at -102.17%
PBDIT(Q)
Lowest at Rs 1.17 cr.
OPERATING PROFIT TO NET SALES (Q)
Lowest at 2.08%
NON-OPERATING INCOME(Q)
is 115.22 % of Profit Before Tax (PBT
EPS(Q)
Lowest at Rs 0.04
Loading Valuation Snapshot...
Here's what is not working for Balaxi Pharma
Net Sales - Quarterly
At Rs 56.18 cr has Fallen at -27.40%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -0.21 cr has Fallen at -102.17%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
At Rs 9.14 cr has Grown at -56.40%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Net Sales - Quarterly
Lowest at Rs 56.18 cr
in the last five quartersMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Lowest at Rs 1.17 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Lowest at 2.08%
in the last five quartersMOJO Watch
Company's efficiency has deteriorated
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -0.21 cr.
in the last five quartersMOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
Non Operating Income - Quarterly
is 115.22 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Earnings per Share (EPS) - Quarterly
Lowest at Rs 0.04
in the last five quartersMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
